clostridium difficile toxoids a and b
Vaccineexperimental
Clinical trial activity
11 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
8
Phase 3
3
Phase 4
0
Earliest trial started Jul 1, 2005 (NCT00127803)
Timeline
Indications
Mechanism of action
- Clostridium difficileImmunity, active
Clostridium difficile immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- clostridium difficile toxoids a and b
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03918629 | Phase 3 | Apr 1, 2019 | Pfizer |
| NCT03579459 | Phase 3 | Jul 31, 2018 | Pfizer |
| NCT03090191 | Phase 3 | Mar 29, 2017 | Pfizer |
| NCT02725437 | Phase 1 | Feb 15, 2016 | Pfizer |
| NCT02561195 | Phase 2 | Jul 16, 2015 | Pfizer |
| NCT02117570 | Phase 2 | Jul 1, 2014 | Pfizer |
| NCT01896830 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2013 | Sanofi, Sanofi-Aventis |
| NCT01230957 | Phase 2 | Oct 1, 2010 | Sanofi |
| NCT00772343 | Phase 2 | Feb 1, 2009 | Sanofi |
| NCT00772954 | Phase 1 | Mar 1, 2006 | Bio-Kinetic Clinical Applications, Sanofi |
| NCT00127803 | Phase 1 | Jul 1, 2005 | Orlando Clinical Research Center, Sanofi, University of Kentucky |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 6 | 6 | 3 | 2014 |
| Sanofi | For profit | 5 | 5 | 2 | 2005 |
| Bio-Kinetic Clinical Applications | For profit | 1 | 0 | 1 | 2006 |
| Orlando Clinical Research Center | For profit | 1 | 0 | 1 | 2005 |
| Sanofi-Aventis | For profit | 1 | 0 | 1 | 2013 |
| University of Kentucky | Academic/Hospital | 1 | 0 | 1 | 2005 |
6 organizations
Page 1 / 1